TY - BOOK ID - 64931061 TI - Treatment Strategies and Survival Outcomes in Breast Cancer PY - 2020 SN - 3039287591 3039287583 PB - MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - relative survival KW - young women KW - cancer treatment KW - n/a KW - fulvestrant KW - lapatinib KW - tumor biology KW - antihormone therapy KW - mastectomy KW - aromatase inhibitors KW - chemotherapy KW - serum biomarker KW - cyclin E KW - anthracycline resistance KW - zero-inflated Poisson regression model KW - lymph-node ratio KW - CHEK2 KW - comparative effectiveness KW - breast-conserving therapy KW - taxane sensitivity KW - liquid biopsy KW - HER2 c-erbB2 KW - colorectal cancer KW - infiltrating breast cancer KW - survival KW - exercise characteristics KW - lactate dehydrogenase KW - biomarker KW - breast cancer survivors KW - BRCA KW - disease-free survival KW - PIK3CA KW - metastatic breast cancer KW - cell-free DNA KW - invasive breast cancer KW - radiotherapy KW - Metformin KW - social well-being KW - gene expression KW - contralateral breast cancer KW - basal-like breast cancer KW - LMK-235 KW - Src kinase KW - HER2/neu KW - LKB1 KW - Older women KW - LDH KW - mutation carriers KW - stage IV KW - mammography screening KW - NCDB KW - cMet KW - SEER KW - pertuzumab KW - physical function KW - outcome KW - ribociclib KW - older patients KW - geriatric oncology KW - metastatic KW - overdiagnosis KW - next-generation sequencing KW - abemaciclib KW - Endocrine therapy KW - monitoring metastatic breast cancer KW - breast cancer KW - circulating tumor cells KW - Breast Cancer KW - PALB2 KW - histone deacetylase KW - prognosis KW - physical activity KW - trastuzumab KW - ductal carcinoma in situ KW - contralateral prophylactic mastectomy KW - ERCC1 KW - family history KW - T-DM1 KW - ATM KW - advanced breast cancer KW - incidence KW - palbociclib KW - HDAC5 inhibitors KW - APOBEC3B UR - https://www.unicat.be/uniCat?func=search&query=sysid:64931061 AB - Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival. ER -